BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Camino and Nittetsu Launch Next Phase of Detailed Engineering for the Puquios Copper Project in Chile with Ausenco27.10.2026 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 27, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that following the successful completion of the Critical Engineering Phase study with Ausenco, the company officially held the kickoff meeting to launch the next phase of detailed engineering services with Ausenco Chile Ltda. ("Ausenco") for the Puquios copper project (the "Puquios Project"). This transition into detailed engineering represents a major step forward in advancing the project, locking in technical specifications, and preparing the Puquios Project for the construction phase. Marcelo Bruna, CEO of the Puquios Joint Venture said, "With the commencement of detailed engineering, the executive team remains focused on strict milestone tracking and cost control as we progress towards breaking ground." Jay Chmelauskas, CEO of Camino further commented, "We are working closely with Nittetsu to finalize agreements to source a pote
Clean Air Metals Announces Auditor Review of Q2 Financial Statements26.10.2026 21:30:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / October 26, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that, as of October 22, 2026, the Company's auditor, Manning Elliott LLP, has completed a review of the Company's second quarter consolidated interim financial statements for the six-month period ended July 31, 2026 (the "Financial Statements"), which were included in the Company's management information circular dated October 14, 2026, in connection with the Company's upcoming annual general and special meeting scheduled for November 13, 2026. No amendments were made to the Financial Statements as a result of the auditor's review, other than the removal of the "Notice of No Auditor Review." Upcoming Annual General and Special Meeting of Shareholders Additionally, Clean Air Metals' shareholders are reminded that the Annual General and Special Meeting of Shareholders (the "Meeting") will be held virtually on November 13, 2026. S
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 202626.10.2026 15:00:00 CET | Press release
MIAMI, FL / ACCESS Newswire / October 26, 2026 / Miami Fashion Week® (MIAFW) celebrated its landmark 10th anniversary October 13-18, 2026, bringing together international designers, Latin American talent and Miami's creative community for six days of runway presentations, industry programming and special events. The milestone edition celebrated a decade of connecting Miami with the international fashion industry while continuing to expand beyond the runway through sustainability, technology, education and cultural exchange. Further strengthening its ties to the local community, MIAFW established a long-term partnership with Miami Dade College and Miami Fashion Institute. Images: Courtesy of Miami Fashion Week "Celebrating 10 years of Miami Fashion Week is an incredibly meaningful milestone," said Lourdes Fernandez-Velasco, Executive Director of Miami Fashion Week. "Over the past decade, we've built a platform that connects designers, creatives and industry leaders from around the world
Chervon Names Parker Wesley Clary Director of Field Sales - Southern Division26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Parker Wesley Clary joins Chervon as Director of Field Sales - Southern Division, effective October 26, 2026, reporting to Thomas Kentouris, VP of Field Sales. Clary assumes responsibility for the Southern Division of the Chervon Field Sales Team. He is charged with developing a strong organization, building outstanding store-level merchandising and promotional programs. Most recently, Parker was a Key Account Manager for TTI/Milwaukee Pro Tools responsible for the Transportation Maintenance Vertical. His impressive career also includes a series of increasingly responsible positions in store coverage and field sales management. "Parker's exceptional sales and sales management skills will help us deliver our bold growth targets," said Thomas Kentouris. "He is a high-potential talent with a bright future ahead at Chervon." "The opportunity to be a part of Chervon's inspired high-performance culture was most compelling to me," said Par
Chervon names Joel Petersheim as Vice President, End User Research and Sales - OPE Commercial USA26.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 26, 2026 / Joel Petersheim joins Chervon as Vice President, End User Research and Sales - OPE Commercial, effective October 26, 2026, reporting to Joe Galli, CEO. Petersheim brings to Chervon 15+ years of experience at TTI/Milwaukee encompassing a series of increasingly responsible positions in sales, key account management, end user marketing, and sales management. Most recently, he held the position of Vice President Industrial Channel Sales - Northeast. Joel's impressive career also includes a series of director level end user marketing leadership roles focused on the MEP Verticals. His track record in converting key end users and in growing sales in each of his past positions was consistently outstanding. "Joel is a tremendous addition to the outstanding leadership team we are building at Chervon," said Joe Galli. "He is a high potential talent with a tremendous track record of success at the account and end user level." "I am enormously i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom